Project

A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction and high immune responsiveness (MO30039/MO43340)– The DANTE Trial A Trial of AIO in collaboration with SAKK

Ongoing - recruitment active · 2024 until 2028

Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment active
Start Date
2024
End Date
2028
Financing
SAKK
Labels
cancer of colon and small intestine
Brief description/objective